Literature DB >> 26891034

Identification of sirtuin 1 as a promising therapeutic target for hypertrophic scars.

Xiao-Zhi Bai1, Jia-Qi Liu1, Long-Long Yang1, Lei Fan1, Ting He1, Lin-Lin Su1, Ji-Hong Shi1, Chao-Wu Tang1, Zhao Zheng1, Da-Hai Hu1.   

Abstract

BACKGROUND AND
PURPOSE: Sirtuin1 (SIRT1), the founding member of mammalian class III histone deacetylases, is reported to be a drug target involved in fibrotic diseases. However, whether it is an effective drug target in hypertrophic scar treatment is still not known. EXPERIMENTAL APPROACH: In the present study, we observed that SIRT1 localized to both the epidermis and the dermis of skin tissues by immunohistochemistry. After knock-down of SIRT1 by shRNA or up-regulating SIRT1 by resveratrol, the expression of α-SMA, Col1 and Col3 in fibroblasts were detected by western blots. A mouse excision wound healing model was used to observe the changes in collagen fibre associated with the different expression levels of SIRT1. KEY
RESULTS: SIRT1 expression was inhibited in hypertrophic scar tissue. The down-regulation of SIRT1 resulted in an increased expression of α-SMA, Col1 and Col3 in hypertrophic scar-derived fibroblasts. In contrast, the up-regulation of SIRT1 not only inhibited the expression of α-SMA, Col1 and Col3 in hypertrophic scar-derived fibroblasts but also blocked the activation of TGFβ1-induced normal skin-derived fibroblasts. In the mouse model of wound healing, the deletion of SIRT1 resulted in denser collagen fibres and a more disordered structure, whereas resveratrol treatment led to a more organized and thinner collagen fibre, which was similar to that observed during normal wound healing. CONCLUSIONS AND IMPLICATIONS: The results revealed that SIRT1 negatively regulates TGFβ1-induced fibroblast activation and inhibits excessive scar formation and is, therefore, a promising drug target for hypertrophic scar formation.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26891034      PMCID: PMC4842923          DOI: 10.1111/bph.13460

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  61 in total

1.  Novel methods for the investigation of human hypertrophic scarring and other dermal fibrosis.

Authors:  Dariush Honardoust; Peter Kwan; Moein Momtazi; Jie Ding; Edward E Tredget
Journal:  Methods Mol Biol       Date:  2013

Review 2.  Histone deacetylases as regulators of inflammation and immunity.

Authors:  Melanie R Shakespear; Maria A Halili; Katharine M Irvine; David P Fairlie; Matthew J Sweet
Journal:  Trends Immunol       Date:  2011-05-12       Impact factor: 16.687

Review 3.  The myofibroblast matrix: implications for tissue repair and fibrosis.

Authors:  Franco Klingberg; Boris Hinz; Eric S White
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

4.  Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages.

Authors:  Hasina Hamilton Outtz; June K Wu; Xing Wang; Jan Kitajewski
Journal:  J Immunol       Date:  2010-08-25       Impact factor: 5.422

5.  Protection against TGF-β1-induced fibrosis effects of IL-10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring.

Authors:  Ji-Hong Shi; Hao Guan; Shan Shi; Wei-Xia Cai; Xiao-Zhi Bai; Xiao-Long Hu; Xiao-Bin Fang; Jia-Qi Liu; Ke Tao; Xiong-Xiang Zhu; Chao-Wu Tang; Da-Hai Hu
Journal:  Arch Dermatol Res       Date:  2013-01-16       Impact factor: 3.017

6.  Effects of histone deacetylase inhibitors on rat mesangial cells.

Authors:  Ilya Freidkin; Michal Herman; Ana Tobar; Avry Chagnac; Yaacov Ori; Asher Korzets; Uzi Gafter
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-18

7.  Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats.

Authors:  Enrique Chávez; Karina Reyes-Gordillo; José Segovia; Mineko Shibayama; Victor Tsutsumi; Paula Vergara; Mario G Moreno; Pablo Muriel
Journal:  J Appl Toxicol       Date:  2008-01       Impact factor: 3.446

8.  SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis.

Authors:  Cíntia dos Santos Costa; Thais Ortiz Hammes; Francieli Rohden; Rogério Margis; Josiane Woutheres Bortolotto; Alexandre Vontobel Padoin; Cláudio Cora Mottin; Regina Maria Guaragna
Journal:  Obes Surg       Date:  2009-12-22       Impact factor: 4.129

9.  Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms.

Authors:  Enrico Conte; Mary Fruciano; Evelina Fagone; Elisa Gili; Filippo Caraci; Maria Iemmolo; Nunzio Crimi; Carlo Vancheri
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

Review 10.  Critical Role of Transforming Growth Factor Beta in Different Phases of Wound Healing.

Authors:  Mohammadreza Pakyari; Ali Farrokhi; Mohsen Khosravi Maharlooei; Aziz Ghahary
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-06       Impact factor: 4.730

View more
  15 in total

Review 1.  Sirtuins in Skin and Skin Cancers.

Authors:  Liz Mariely Garcia-Peterson; Melissa Jean Wilking-Busch; Mary Ann Ndiaye; Christine Gaby Azer Philippe; Vijayasaradhi Setaluri; Nihal Ahmad
Journal:  Skin Pharmacol Physiol       Date:  2017-07-14       Impact factor: 3.479

2.  Identification of sirtuin 1 as a promising therapeutic target for hypertrophic scars.

Authors:  Xiao-Zhi Bai; Jia-Qi Liu; Long-Long Yang; Lei Fan; Ting He; Lin-Lin Su; Ji-Hong Shi; Chao-Wu Tang; Zhao Zheng; Da-Hai Hu
Journal:  Br J Pharmacol       Date:  2016-03-23       Impact factor: 8.739

Review 3.  Sirtuins and Accelerated Aging in Scleroderma.

Authors:  Anne E Wyman; Sergei P Atamas
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

Review 4.  Biological approaches for hypertrophic scars.

Authors:  Zhong Lingzhi; Li Meirong; Fu Xiaobing
Journal:  Int Wound J       Date:  2019-12-20       Impact factor: 3.315

5.  Adipose tissue-derived stem cells suppress hypertrophic scar fibrosis via the p38/MAPK signaling pathway.

Authors:  Yan Li; Wei Zhang; Jianxin Gao; Jiaqi Liu; Hongtao Wang; Jun Li; Xuekang Yang; Ting He; Hao Guan; Zhao Zheng; Shichao Han; Maolong Dong; Juntao Han; Jihong Shi; Dahai Hu
Journal:  Stem Cell Res Ther       Date:  2016-08-02       Impact factor: 6.832

6.  Resveratrol-loaded peptide-hydrogels inhibit scar formation in wound healing through suppressing inflammation.

Authors:  Chen-Chen Zhao; Lian Zhu; Zheng Wu; Rui Yang; Na Xu; Liang Liang
Journal:  Regen Biomater       Date:  2019-10-30

7.  Keloid risk in patients with atopic dermatitis: a nationwide retrospective cohort study in Taiwan.

Authors:  Ying-Yi Lu; Chun-Ching Lu; Wei-Wen Yu; Li Zhang; Qing-Rui Wang; Cong-Liang Zhang; Chieh-Hsin Wu
Journal:  BMJ Open       Date:  2018-07-18       Impact factor: 2.692

8.  The Akt/FoxO/p27Kip1 axis contributes to the anti-proliferation of pentoxifylline in hypertrophic scars.

Authors:  Fangfang Yang; Erfei Chen; Yunshu Yang; Fu Han; Shichao Han; Gaofeng Wu; Min Zhang; Jian Zhang; Juntao Han; Linlin Su; Dahai Hu
Journal:  J Cell Mol Med       Date:  2019-07-03       Impact factor: 5.310

9.  Epidermal SIRT1 regulates inflammation, cell migration, and wound healing.

Authors:  Lei Qiang; Ashley Sample; Han Liu; Xiaoyang Wu; Yu-Ying He
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

Review 10.  Current Therapeutic Approach to Hypertrophic Scars.

Authors:  Zrinka Bukvić Mokos; Anamaria Jović; Lovorka Grgurević; Ivo Dumić-Čule; Krešimir Kostović; Romana Čeović; Branka Marinović
Journal:  Front Med (Lausanne)       Date:  2017-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.